research

Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call Transcript

Seeking Alpha

2 min read

0 likes

⚡ Quantum Brief

Lineage Cell Therapeutics reported Q4 and full-year 2025 financial results on March 5, 2026, highlighting key operational milestones and financial performance during the earnings call. CEO Brian Culley outlined progress in clinical trials, emphasizing advancements in their lead cell therapy programs, including updated timelines for regulatory submissions and potential commercialization pathways. CFO Jill Howe detailed financials, noting a year-over-year revenue decline but improved cost management, with cash reserves projected to fund operations into late 2027 pending no major setbacks. Analysts questioned pipeline priorities, particularly the OpRegen program for dry AMD, with management reaffirming its focus on high-value indications despite competitive pressures in the regenerative medicine sector. Forward-looking statements dominated discussions, with leadership cautioning about risks tied to clinical trial outcomes, regulatory hurdles, and funding requirements for scaling manufacturing capabilities.

AI Audio Summary

0:00 / 0:00

Click to play

Quantum News · Media Library

Understand this faster with AI

Ask ChatGPT

Research with Perplexity

Explain with Claude

Discuss on Grok

SA Transcripts158.84K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Lineage Cell Therapeutics, Inc. (LCTX) Q4 2025 Earnings Call March 5, 2026 4:30 PM EST Company Participants Ioana Hone - Director of Investor RelationsBrian Culley - CEO, President & DirectorJill Howe - CFO & Principal Financial and Accounting Officer Conference Call Participants Joseph Pantginis - H.C. Wainwright & Co, LLC, Research DivisionJack Allen - Robert W. Baird & Co. Incorporated, Research DivisionMayank Mamtani - B. Riley Securities, Inc., Research DivisionGum-Ming Lowe - Craig-Hallum Capital Group LLC, Research DivisionYang Chen - Raymond James & Associates, Inc., Research Division Presentation Operator Welcome to the Lineage Cell Therapeutics Third (sic) [ Fourth ] Quarter 2025 Conference Call. [Operator Instructions] An audio webcast of this call is available on the Investors section of Lineage's website at www.lineagecell.com. This call is subject to copyright and is the property of Lineage. And recordings, reproductions or transmission of this call without the expressed written consent of Lineage are strictly prohibited. As a reminder, today's call is being recorded. I would now like to introduce your host for today's call, Ioana Hone, Head of Investor Relations at Lineage. Ms. Hone, please go ahead. Ioana HoneDirector of Investor Relations Thank you, Jamie. Good afternoon, and thank you for joining us. A press release reporting our fourth quarter and full year 2025 financial results was issued earlier today, March 5, 2026, and can be found on the Investors section of our website. Please note that today's remarks and responses to your questions reflect management's views as of today only and will contain forward-looking statements within the meaning of federal securities laws. Statements made during this discussion that are not statements of historical fact should be considered forward-looking statements, which are subject to significant risks and uncertainties. The company's actual results or performance may differ materially from the expectations indicated by

Read Original

Source Information

Source: Seeking Alpha

Website: https://seekingalpha.com/feed.xml

Discussion

0 professional contributions

Be the first to add a constructive contribution.